# A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

> **NCT06980805** · PHASE2 · RECRUITING · sponsor: **Immunovant Sciences GmbH** · enrollment: 56 (estimated)

## Conditions studied

- Subacute Cutaneous Lupus Erythematosus
- Chronic Cutaneous Lupus Erythematosus

## Interventions

- **DRUG:** IMVT-1402
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06980805
- **Lead sponsor:** Immunovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-19
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06980805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06980805, "A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06980805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*